Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

United Therapeutics Remodulin

Executive Summary

United Therapeutics will resubmit NDA for Remodulin Aug. 10 if the product receives a positive review from FDA's Cardiovascular & Renal Drugs Advisory Committee Aug. 9. The company withdrew the application for Remodulin (formerly Uniprost) for pulmonary arterial hypertension shortly before the product's July 16 user fee deadline. "Because the Aug. 9 advisory committee meeting fell outside the [Prescription Drug Use Fee Act] time period, the company was required to withdraw its NDA and will resubmit it upon a favorable advisory committee recommendation by the following day, Aug. 10," United Therapeutics said
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS038320

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel